Immix Biopharma Inc./$IMMX
1D1W1MYTD1Y5YMAX
About Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
- Ticker
- $IMMX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- Los Angeles, United States
- Website
- www.immixbio.com
IMMX Metrics
BasicAdvanced
$1B
-
-$0.83
0.11
-
Price and volume
Market cap
$1B
Beta
0.11
52-week high
$15.10
52-week low
$1.94
Average daily volume
1.7M
Financial strength
Current ratio
25.134
Quick ratio
24.953
Long term debt to equity
0.389
Total debt to equity
0.438
Profitability
EBITDA (TTM)
-41.484
Effective tax rate (TTM)
-0.08%
Management effectiveness
Return on assets (TTM)
-20.52%
Return on equity (TTM)
-34.18%
Valuation
Price to book
4.52
Price to tangible book (TTM)
4.52
Price to free cash flow (TTM)
-17.709
Free cash flow yield (TTM)
-5.65%
Free cash flow per share (TTM)
-0.817
Growth
Earnings per share change (TTM)
7.06%
3-year earnings per share growth (CAGR)
1.31%
IMMX News
AllArticlesVideos
IMMX Investors Have Opportunity to Join Immix Biopharma, Inc. Fraud Investigation with SBS Law
Business Wire3 weeks ago
IMMX INVESTIGATION: Securities Fraud Investigation by Block & Leviton Could Allow Immix Biopharma Investors to Recover Losses
Newsfile Corp1 month ago
Immix Biopharma Stock Drops Significantly On News of Chief Medical Officer Arrest - IMMX Investors Encouraged to Contact Kehoe Law Firm, P.C. Regarding Potential Securities Fraud Claims
Newsfile Corp1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.